The high cost of prescription drugs continues to burden patients and taxpayers. Surveys have shown that about three in ten adults do not take their medicines as prescribed because of the cost. Policymakers and regulators continue to explore various policies and enforcement actions to address the key drivers of high drug prices, address market distortions, and ensure patients and their families can access life-saving treatments. At the same time, challengers are actively pursuing several strategies, including litigation, that could frustrate state and federal measures that address prescription drug affordability.
ISSUE
Prescription Drug Affordability
Issue Metadata
Prescription Drug Affordability tracked topics
-
Orange Book Patent Listings
Cases Tracked: 4
-
Product Specific Access Laws
Cases Tracked: 4
-
Price Gouging Laws
Cases Tracked: 3
-
Prescription Drug Affordability Boards
Cases Tracked: 2
-
Transparency Laws
Cases Tracked: 2
Important Date
Petition for Rehearing Due
Dive Deeper
O'Neill Institute
State Action to Lower Prescription Drug Prices: Navigating Patent PreemptionO'Neill Institute
A Setback for Prescription Drug Pricing: Eighth Circuit Rolls Back Minnesota Drug Price-Gouging LawO'Neill Institute
Pharmaceutical Industry Seeks to Thwart State Initiatives to Tackle Unaffordability of Prescription DrugsMore Issues
- 340B Program 15 cases
- Affordable Care Act 65 cases 6 Topics
- Anticompetitive Practices 20 cases
- Artificial Intelligence 3 cases
- Consumer Protections 10 cases
- Cost Containment 12 cases
- Equity 48 cases 1 Topics
- ERISA 15 cases
- Federal Health Funding 31 cases 4 Topics
- Health Information 2 cases
- Medicare Advantage 4 cases
- Medicare Drug Price Negotiation 20 cases
- No Surprises Act 34 cases 4 Topics
- Reproductive Health 39 cases 5 Topics
- Site-Neutral Payments 9 cases
- Transparency 5 cases